Company research
MARINUS PHARMACEUTICALS, INC.
CIK 1267813Updated Sep 26, 2026
Name history
MARINUS PHARMACEUTICALS INC · through Mar 31, 2022
Filing activity
Latest filing
50 filings on record · SCHEDULE 13G/A, 15-12G, EFFECT, SCHEDULE 13G, 4, 25-NSE.
About the company
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. Marinus’ product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the United States in 2022. For more information, please visit www.marinuspharma.com and follow us on Facebook, LinkedIn and X.
Recent filings
SCHEDULE 13G/A - filed by Beryl Capital Management LLC regarding MARINUS PHARMACEUTICALS, INC.
SCHEDULE 13G/A - filed by MORGAN STANLEY regarding MARINUS PHARMACEUTICALS, INC.
15-12G filing
SCHEDULE 13G/A - filed by Panacea Innovation Ltd regarding MARINUS PHARMACEUTICALS, INC.
SCHEDULE 13G/A - filed by TANG CAPITAL PARTNERS LP regarding MARINUS PHARMACEUTICALS, INC.
Financials
FY 2023 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 170,908,000Source | 259,518,000Source | 136,840,000Source | 150,462,000Source |
| Property, Plant and Equipment, NetUSD | 3,843,000Source | 4,236,000Source | 2,499,000Source | 1,945,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 120,572,000Source | 240,551,000Source | 122,927,000Source | 138,509,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,799,000Source | 6,348,000Source | 2,629,000Source | — |
| Inventory, NetUSD | 2,413,000Source | 77,000Source | — | — |
| Assets, CurrentUSD | 165,246,000Source | 252,378,000Source | 131,678,000Source | 146,267,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,746,000Source | 5,402,000Source | 5,565,000Source | 4,638,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,000,000Source | 1,300,000Source | 1,700,000Source | 2,000,000Source |
| Other Assets, NoncurrentUSD | 1,819,000Source | 2,904,000Source | 2,663,000Source | 2,250,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 154,143,000Source | 143,518,000Source | 83,354,000Source | 13,263,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 4,043,000Source | 4,302,000Source | 4,469,000Source |
| Common Stock, Value, IssuedUSD | 55,000Source | 50,000Source | 37,000Source | 37,000Source |
| Additional Paid in CapitalUSD | 588,656,000Source | 542,428,000Source | 459,852,000Source | 444,622,000Source |
| Retained Earnings (Accumulated Deficit)USD | -571,926,000Source | -430,521,000Source | -410,705,000Source | -311,929,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -20,000Source | — | — | — |
| Stockholders' Equity Attributable to ParentUSD | 16,765,000Source | 116,000,000Source | 53,486,000Source | 137,199,000Source |
| Liabilities and EquityUSD | 170,908,000Source | 259,518,000Source | 136,840,000Source | 150,462,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 40,624,000Source | 25,017,000Source | 40,566,000Source | 10,729,000Source |
| Operating Lease, Liability, CurrentUSD | 774,000Source | 637,000Source | 556,000Source | 510,000Source |
| Accounts Payable, CurrentUSD | 4,003,000Source | 4,461,000Source | 3,126,000Source | 2,211,000Source |
| Operating Lease, Liability, NoncurrentUSD | 633,000Source | 1,341,000Source | 1,979,000Source | 2,534,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 22,859,000Source | 19,536,000Source | 16,207,000Source | 8,518,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 150,300,000Source | — | — | — |
| Long-term DebtUSD | 75,000,000Source | 75,000,000Source | 45,000,000Source | — |
| Short-term InvestmentsUSD | — | — | — | 1,474,000Source |
cash flow · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -141,405,000Source | -19,816,000Source | -98,776,000Source | -67,475,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 15,563,000Source | 14,890,000Source | 13,867,000Source | 7,642,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -118,001,000Source | -112,886,000Source | -55,477,000Source | -60,912,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -28,605,000Source | 105,772,000Source | -1,415,000Source | -738,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 26,627,000Source | 124,738,000Source | 41,310,000Source | 109,216,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -119,979,000Source | 117,624,000Source | -15,582,000Source | 47,566,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 120,572,000Source | 240,551,000Source | 122,927,000Source | 138,509,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 8,697,000Source | 7,892,000Source | — | — |
| Income Taxes Paid, NetUSD | 903,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 15,563,000Source | 13,169,000Source | 13,588,000Source | — |
| Amortization of Debt Issuance CostsUSD | 2,248,000Source | 1,663,000Source | 549,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 150,300,000Source | — | — | — |
| DepreciationUSD | 551,000Source | 418,000Source | 355,000Source | 334,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | -930,000Source | 930,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | -243,000Source | — |
| General and Administrative ExpenseUSD | — | — | 37,278,000Source | 18,549,000Source |
| Income Tax Expense (Benefit)USD | -1,538,000Source | 3,389,000Source | — | — |
| Investment Income, InterestUSD | 8,113,000Source | 2,354,000Source | 80,000Source | 499,000Source |
| Net Income (Loss) Attributable to ParentUSD | -141,405,000Source | -19,816,000Source | -98,776,000Source | -67,475,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -141,405,000Source | -19,816,000Source | -98,776,000Source | -76,355,000Source |
| Operating Lease, Impairment LossUSD | 0Source | 0Source | 0Source | — |
| Other Nonoperating Income (Expense)USD | 1,324,000Source | -2,696,000Source | 657,000Source | -37,000Source |
| Payments of Financing CostsUSD | — | — | 148,000Source | — |
| Payments to Acquire InvestmentsUSD | 51,995,000Source | — | — | 8,931,000Source |
| Proceeds from Stock Options ExercisedUSD | 804,000Source | 1,794,000Source | 1,199,000Source | 1,020,000Source |
income statement · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | 8,987,000Source | — |
| Cost of RevenueUSD | — | — | 1,478,000Source | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 61,152,000Source | 56,845,000Source | — | — |
| Operating Income (Loss)USD | -131,485,000Source | -112,788,000Source | -96,931,000Source | -67,937,000Source |
| Other Nonoperating Income (Expense)USD | 1,324,000Source | -2,696,000Source | 657,000Source | -37,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -142,943,000Source | -16,427,000Source | -98,776,000Source | — |
| Income Tax Expense (Benefit)USD | -1,538,000Source | 3,389,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -141,405,000Source | -19,816,000Source | -98,776,000Source | -67,475,000Source |
| Earnings Per Share, BasicUSD per share | -2.63Source | -0.51Source | -2.69Source | — |
| Earnings Per Share, DilutedUSD per share | -2.63Source | -0.51Source | -2.69Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 53,746,518Source | 39,072,599Source | 36,697,171Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 53,746,518Source | 39,072,599Source | 36,663,340Source | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 162,474,000Source | 138,266,000Source | 112,276,000Source | — |
| Current Income Tax Expense (Benefit)USD | -1,538,000Source | 3,389,000Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 500,000Source | 300,000Source | 300,000Source | 300,000Source |
| General and Administrative ExpenseUSD | — | — | 37,278,000Source | 18,549,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -142,943,000Source | -16,427,000Source | -98,776,000Source | -67,475,000Source |
| Interest ExpenseUSD | 16,895,000Source | 10,672,000Source | 2,582,000Source | — |
| Investment Income, InterestUSD | 8,113,000Source | 2,354,000Source | 80,000Source | 499,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -141,405,000Source | -19,816,000Source | -98,776,000Source | -76,355,000Source |
| Research and Development ExpenseUSD | 99,388,000Source | 79,912,000Source | 73,520,000Source | 51,106,000Source |
Filing attachments
tm256024d9_ex99-1.htm · 8-K · 2025-02-11
EX-99.1 4 tm256024d9_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press release Immedica completes acquisition of Marinus Pharmaceuticals, Inc. Stockholm, Sweden - February 11, 2025 - Immedica Pharma AB (“Immedica”), a leading global rare disease company, announced today the completion of the acquisition of Marinus Pharmaceuticals, Inc. (“Marinus”) (Nasdaq: MRNS) through its indirect wholly owned subsidiary Matador Subsidiary, Inc., a Delaware corporation (“Purchaser”). Following the completi…
Read attachment ↗